Bloomberg Talks Lilly CEO Talks Fighting Cancer and Obesity, Drug Pricing
8 snips
Jan 13, 2025 Dave Ricks, CEO of Eli Lilly, dives into the company's bold $2.5 billion acquisition of Scorpion Therapeutics' breast cancer program, signaling a major commitment to oncology. He discusses the anticipated approval of Lilly's innovative oral weight-loss pill in early 2026 and its potential advantages over current treatments. Ricks also addresses the critical issue of drug pricing, exploring strategies for making new medications accessible while ensuring they deliver value and effective outcomes.
AI Snips
Chapters
Transcript
Episode notes
Lilly's Oncology Acquisition
- Eli Lilly is acquiring Scorpion Therapeutics' breast cancer program for $2.5 billion.
- This adds to Lilly's growing oncology portfolio, including the successful drug Verzenio.
Diverse Portfolio at Lilly
- Eli Lilly's portfolio is not solely focused on weight loss.
- It encompasses four therapeutic areas: diabetes/weight loss, oncology, immunology, and neuroscience.
M&A Strategy
- Eli Lilly's M&A strategy focuses on early-stage acquisitions in familiar therapeutic areas.
- This approach allows them to take calculated risks and build a strong pipeline.